Going More Than Skin Deep Into Merz’s Ulthera Acquisition

New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.

As the hurdles for regulatory approval and reimbursement have risen higher, medtech investors often have pursued investments in aesthetics companies. In contrast to more traditional medtech, aesthetics companies typically aren’t required to conduct stringent clinical testing as they can bring a product to market with a 510(k) notification from the Food and Drug Administration. Also, patients eager to maintain the appearance of youth and good health are willing to pay for procedures out of their own pockets. This enables aesthetics companies to avoid the byzantine reimbursement process.

However, for venture investors, the lowest hanging fruit isn’t always the most nutritious. Venture capital investment exits from aesthetics companies...

More from Deal-Making

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.